Inovio Pharmaceuticals (INO) to Release Earnings on Thursday

Inovio Pharmaceuticals (NASDAQ:INO) is expected to announce its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Inovio Pharmaceuticals Stock Performance

INO stock opened at $1.73 on Tuesday. Inovio Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $2.98. The stock has a market capitalization of $115.44 million, a price-to-earnings ratio of -0.67 and a beta of 1.70. The stock’s fifty day moving average is $1.65 and its two-hundred day moving average is $2.06.

Wall Street Analysts Forecast Growth

INO has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 29th. Piper Sandler restated an “overweight” rating and issued a $6.00 target price (up from $5.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th. Finally, UBS Group reaffirmed an “overweight” rating on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $6.75.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of INO. Virtu Financial LLC acquired a new position in Inovio Pharmaceuticals during the 4th quarter valued at about $77,000. Janus Henderson Group PLC raised its position in shares of Inovio Pharmaceuticals by 1.3% during the 4th quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock worth $5,773,000 after buying an additional 42,146 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Inovio Pharmaceuticals in the 4th quarter worth approximately $301,000. 683 Capital Management LLC bought a new position in shares of Inovio Pharmaceuticals in the fourth quarter valued at approximately $433,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $388,000. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.